Clene Inc. (CLNN) insider entity sells common shares in January

Rhea-AI Filing Summary

Symbiosis II, LLC, an entity associated with 10% owner Chidozie Ugwumba, reported multiple sales of Clene Inc. common stock. On January 8, 2026, it sold 3,195 shares at $6.09 per share, leaving 750,367 shares indirectly owned. On January 9, 2026, it sold 9,075 shares at $6.27 per share, leaving 741,292 shares indirectly owned. On January 12, 2026, it sold 32,705 shares at $5.50 per share, leaving 708,587 shares of Clene common stock held indirectly through Symbiosis II, LLC.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ugwumba Chidozie

(Last) (First) (Middle)

609 SW 8TH STREET

SUITE 510

(Street)

BENTONVILLE AR 72712

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Clene Inc. [ CLNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/08/2026		S		3,195	D	$6.09	750,367	I	By Symbiosis II, LLC
Common Stock	01/09/2026		S		9,075	D	$6.27	741,292	I	By Symbiosis II, LLC
Common Stock	01/12/2026		S		32,705	D	$5.5	708,587	I	By Symbiosis II, LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/Chidozie Ugwumba	01/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who reported the insider transactions in Clene Inc. (CLNN)?

The reported transactions involve Chidozie Ugwumba, identified as a 10% owner of Clene Inc., with the shares held indirectly through Symbiosis II, LLC.

How many Clene Inc. shares did Symbiosis II, LLC sell according to this Form 4?

The Form 4 reports three separate sales of Clene Inc. common stock: 3,195 shares on January 8, 2026, 9,075 shares on January 9, 2026, and 32,705 shares on January 12, 2026.

What prices were received for the Clene Inc. (CLNN) shares sold?

The reported sale prices for Clene Inc. common stock were $6.09 per share on January 8, 2026, $6.27 per share on January 9, 2026, and $5.50 per share on January 12, 2026.

How many Clene Inc. shares were held after the reported transactions?

Following the reported sales, 708,587 shares of Clene Inc. common stock were shown as beneficially owned indirectly through Symbiosis II, LLC as of the January 12, 2026 transaction.

Are the Clene Inc. shares held directly by Chidozie Ugwumba?

No. The Form 4 reports the ownership form as Indirect (I), with the nature of ownership described as "By Symbiosis II, LLC" for the Clene Inc. common stock.

Does this Form 4 report any derivative securities for Clene Inc. (CLNN)?

The section for Table II - Derivative Securities is present, but no derivative transactions or holdings are listed for Clene Inc. in the provided content.